ID23775A - TOPICAL PROVISION OF OXSZOLIDINONA COMPOUNDS FOR TRANSDERMAL INTRODUCTION - Google Patents

TOPICAL PROVISION OF OXSZOLIDINONA COMPOUNDS FOR TRANSDERMAL INTRODUCTION

Info

Publication number
ID23775A
ID23775A IDP990479D ID990479D ID23775A ID 23775 A ID23775 A ID 23775A ID P990479 D IDP990479 D ID P990479D ID 990479 D ID990479 D ID 990479D ID 23775 A ID23775 A ID 23775A
Authority
ID
Indonesia
Prior art keywords
topical
oxszolidinona
provision
compounds
transdermal introduction
Prior art date
Application number
IDP990479D
Other languages
Indonesian (id)
Inventor
Charles W Ford
Jeffrey L Watts
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of ID23775A publication Critical patent/ID23775A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Disclosed is a method of treating a non-topical infection selected from the group consisting of ear infections, skin and soft tissue infections, acne, infected wounds, bacteremia, in a useful warm blooded mammal who is in need of such treatment which comprises topical administration of a pharmaceutical formulation containing a transdermally effective amount of an Oxazolidinone.
IDP990479D 1998-06-05 1999-05-24 TOPICAL PROVISION OF OXSZOLIDINONA COMPOUNDS FOR TRANSDERMAL INTRODUCTION ID23775A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8828398P 1998-06-05 1998-06-05

Publications (1)

Publication Number Publication Date
ID23775A true ID23775A (en) 2000-05-11

Family

ID=22210475

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP990479D ID23775A (en) 1998-06-05 1999-05-24 TOPICAL PROVISION OF OXSZOLIDINONA COMPOUNDS FOR TRANSDERMAL INTRODUCTION

Country Status (29)

Country Link
US (2) US6613349B2 (en)
EP (1) EP1083900B1 (en)
JP (1) JP2002516852A (en)
KR (1) KR100626781B1 (en)
CN (1) CN1168447C (en)
AT (1) ATE220548T1 (en)
AU (1) AU749523B2 (en)
BR (1) BR9910318A (en)
CA (1) CA2327326A1 (en)
CO (1) CO5011042A1 (en)
CZ (1) CZ292420B6 (en)
DE (1) DE69902170T2 (en)
DK (1) DK1083900T3 (en)
EA (1) EA003699B1 (en)
ES (1) ES2179658T3 (en)
HK (1) HK1036593A1 (en)
HU (1) HU225234B1 (en)
ID (1) ID23775A (en)
IL (1) IL139843A0 (en)
MY (1) MY122454A (en)
NO (1) NO20006161L (en)
NZ (1) NZ508636A (en)
PL (1) PL193535B1 (en)
PT (1) PT1083900E (en)
SK (1) SK285352B6 (en)
TR (1) TR200003205T2 (en)
TW (1) TWI224000B (en)
WO (1) WO1999062504A2 (en)
ZA (1) ZA200005886B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562820B2 (en) 2000-07-05 2003-05-13 Pharmacia & Upjohn Company Method for treatment and prevention of mastitis
US20030096850A1 (en) * 2001-10-11 2003-05-22 Ford Charles W. Treating infections by administration of oxazolidinones
RU2354372C2 (en) * 2002-03-29 2009-05-10 Фармация Энд Апджон Компани Ллс Parenteral intravenous and peroral introduction of oxazolidinones for treatment of infectious foot lesions in diabetes
US20060222692A1 (en) * 2005-03-31 2006-10-05 Fairfield Clinical Trials Llc Method and compositions for transdermal administration of antimicrobial medications
CN112409285A (en) * 2020-11-30 2021-02-26 山东金城昆仑药业有限公司 Crystal form of oxazolidinone compound, preparation method and application thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743727A (en) 1970-11-16 1973-07-03 Crown Zellerbach Corp Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide
US4507287A (en) 1983-06-20 1985-03-26 Dixon Glen J Preparation and method for the treatment of acne
JP2558107B2 (en) 1986-12-18 1996-11-27 第一製薬株式会社 Topical
US4943435A (en) 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4960771A (en) 1988-07-12 1990-10-02 Rajadhyaksha Vithal J Oxazolidinone penetration enhancing compounds
US5254577A (en) * 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5164510A (en) 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
US5231188A (en) 1989-11-17 1993-07-27 The Upjohn Company Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents
US5143928A (en) * 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
DK0610265T3 (en) 1991-11-01 1997-06-09 Upjohn Co Substituted aryl and heteroarylphenyloxazolid ions which can be used as antibacterial agents
TW203552B (en) * 1992-02-18 1993-04-11 J Baroody Lloyd Compositions of clindamycin and benzoyl peroxide for acne treatment
US5457194A (en) * 1993-03-17 1995-10-10 Abbott Laboratories Substituted aliphatic amine-containing macrocyclic immunomodulators
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
WO1995014684A1 (en) * 1993-11-22 1995-06-01 The Upjohn Company Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones
DE4425613A1 (en) 1994-07-20 1996-01-25 Bayer Ag 5-membered heteroaryl oxazolidinones
DE4425612A1 (en) 1994-07-20 1996-04-04 Bayer Ag 6-membered nitrogen-containing heteroaryl oxazolidinones
DE69517816T2 (en) 1994-09-14 2000-12-28 Minnesota Mining & Mfg MATRIX FOR TRANSDERMAL ACTIVE SUBSTANCE RELEASE
US5604262A (en) * 1995-03-22 1997-02-18 Research Corporation Technologies, Inc. Topical antimicrobial agents
ZA968661B (en) * 1995-11-17 1998-04-14 Upjohn Co Oxazolidinone antibacterial agent with tricyclic substituents.
EP0898477B1 (en) * 1996-05-10 2002-12-18 PHARMACIA & UPJOHN COMPANY Topical administration of premafloxacin for the treatment of systemic bacterial diseases
US5929086A (en) 1996-05-10 1999-07-27 Pharmacia & Upjohn Company Topical administration of antimicrobial agents for the treatment of systemic bacterial diseases
US6040306A (en) * 1997-11-18 2000-03-21 Pharmacia & Upjohn Company Method of treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy
US6312715B1 (en) 1998-05-01 2001-11-06 3M Innovative Properties Company Adhesive microsphere drug delivery composition
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain

Also Published As

Publication number Publication date
NO20006161D0 (en) 2000-12-04
CA2327326A1 (en) 1999-12-09
ATE220548T1 (en) 2002-08-15
JP2002516852A (en) 2002-06-11
PL193535B1 (en) 2007-02-28
IL139843A0 (en) 2002-02-10
US20020009483A1 (en) 2002-01-24
EP1083900A2 (en) 2001-03-21
CZ20004432A3 (en) 2001-03-14
CN1298302A (en) 2001-06-06
HU225234B1 (en) 2006-08-28
PT1083900E (en) 2002-12-31
EA200100010A1 (en) 2001-06-25
ZA200005886B (en) 2002-04-22
US20040072841A1 (en) 2004-04-15
WO1999062504A3 (en) 2000-02-24
CN1168447C (en) 2004-09-29
TWI224000B (en) 2004-11-21
NO20006161L (en) 2000-12-04
HUP0102191A3 (en) 2003-07-28
SK285352B6 (en) 2006-11-03
AU4184899A (en) 1999-12-20
BR9910318A (en) 2001-01-30
DE69902170D1 (en) 2002-08-22
DE69902170T2 (en) 2003-03-13
US7892574B2 (en) 2011-02-22
SK16262000A3 (en) 2001-06-11
ES2179658T3 (en) 2003-01-16
DK1083900T3 (en) 2002-11-04
EA003699B1 (en) 2003-08-28
PL345119A1 (en) 2001-12-03
KR20010052555A (en) 2001-06-25
HK1036593A1 (en) 2002-01-11
CO5011042A1 (en) 2001-02-28
CZ292420B6 (en) 2003-09-17
HUP0102191A2 (en) 2002-05-29
MY122454A (en) 2006-04-29
KR100626781B1 (en) 2006-09-22
NZ508636A (en) 2002-03-01
EP1083900B1 (en) 2002-07-17
WO1999062504A2 (en) 1999-12-09
AU749523B2 (en) 2002-06-27
TR200003205T2 (en) 2001-05-21
US6613349B2 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
Reyzelman et al. Are antibiotics necessary in the treatment of locally infected ingrown toenails?
HUP9901991A2 (en) Transdermal device for the delivery of flurbiprofen
EP1330221A4 (en) Medical compositions, dressings and methods for treating microbial infections of skin lesions
DK0806941T3 (en) Low firm liposomal antibacterial preparation
BRPI9908182C1 (en) matrix protein compositions for wound healing
WO2001028491A3 (en) Method and composition for the treatment of dermatologic diseases
WO2005007072A3 (en) Methods and pharmaceutical compositions for healing wounds
US4735802A (en) Topical dermatological composition and method of treatment
AU1865100A (en) Hyaluronate lyase used for promoting penetration in topical agents
CA2411922A1 (en) Composition for pain mediation and apparatus and method of use thereof
AU3902299A (en) Methods of treating microbial infection and therapeutic formulations therefor
Nolting Non-traumatic removal of the nail and simultaneous treatment of onychomycosis
ID23775A (en) TOPICAL PROVISION OF OXSZOLIDINONA COMPOUNDS FOR TRANSDERMAL INTRODUCTION
DK1455849T3 (en) Wound Care device
NO20010202L (en) Oxazolidinones to treat eye infections
BR0014751A (en) Compound, stereoisomer or mixture of stereoisomers, pharmaceutical composition, method of treating a patient in need of antimicrobial treatment, and use of a compound
ECSP992967A (en) TOPICAL APPLICATION OF OXAZOLIDINONES FOR TRANSDERMIC ADMINISTRATION
US20130045269A1 (en) Formulations and methods for wound treatment
DK1150981T3 (en) Therapeutic necleoside compound
TH57851B (en) Topical oxasolidinone for transdermal delivery
TNSN03022A1 (en) Method for treatment of inflammation
NO20030483D0 (en) Associations of dalfopristine / quinupristine with cefpiroma